Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag + r-ATG + CsA in treatment-naive severe aplastic anemia
NCT04328727Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of eltrombopag in aplastic anemia, sponsored by Novartis. Started Nov 2020; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT04328727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328727.